Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 10/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3190029 | 0.88 | HDAC3 (0.49) | JAK2JAK1JAK3PTK2PRKCQ | |
| SCHEMBL3179929 | 0.87 | IKBKB (0.44) | JAK3PTK2PRKCQSTAT6 | |
| SCHEMBL3187807 | 0.87 | SIRT5 (0.49) | STAT6APP | |
| SCHEMBL3191032 | 0.86 | VNN1 (0.43) | RPS6KB1AURKA | |
| SCHEMBL3182583 | 0.84 | PRKCQ (0.61) | NTRK1PRKCQ | |
| SCHEMBL3192454 | 0.84 | HDAC3 (0.41) | NTRK1JAK3STAT6MAPK1 | |
| SCHEMBL3189750 | 0.84 | HDAC3 (0.51) | NTRK1STAT6BRAFMAPK1 | |
| SCHEMBL3190916 | 0.82 | SCD (0.48) | STAT6RPS6KB1AURKA | |
| SCHEMBL4385162 | 0.81 | NTRK1 (0.49) | NTRK1JAK2JAK1JAK3PTK2 | |
| SCHEMBL3186194 | 0.81 | VNN1 (0.46) | JAK3PTK2PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113463-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7662819-B2 | Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD PALO ALTO, INC. (US) | 2010-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113463-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, COASY | NTRK1 4852/4885JAK2 4357/4885JAK1 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.